HER-2-Targeted Nanoparticle-Affibody Bioconjugates for Cancer Therapy

被引：114

作者：

Alexis, Frank ^{[1
,2
,3
]}

Basto, Pamela ^{[2
,3
]}

Levy-Nissenbaum, Etgar ^{[1
,2
,3
]}

Radovic-Moreno, Aleksandar F. ^{[3
]}

Zhang, Liangfang ^{[3
]}

Pridgen, Eric ^{[4
]}

Wang, Andrew Z. ^{[2
,3
,5
]}

Marein, Shawn L. ^{[1
,2
]}

Westerhof, Katrina ^{[1
,2
,3
]}

Molnar, Linda K. ^{[6
]}

Farokhzad, Omid C. ^{[1
,2
,3
]}

机构：

[1] Brigham & Womens Hosp, Dept Anesthesiol, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Boston, MA 02115 USA

[3] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA

[4] MIT, Dept Chem Engn, Cambridge, MA 02139 USA

[5] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA

[6] NCI, NIH, Bethesda, MD 20892 USA

来源：

CHEMMEDCHEM | 2008年 / 3卷 / 12期

基金：

美国国家卫生研究院;

关键词：

targeted therapy; antitumor agents; affibodies; nanoparticles; PLA-PEG copolymers;

D O I：

10.1002/cmdc.200800122

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

(Figure Presented) Affibodies are a class of polypeptide ligand that are potential candidates for tissue-specific targeting of drug-encapsulated controlled release polymeric nanoparticles (NPs). We developed drug delivery vehicles composed of polymeric NPs surface modified with affibody ligands that bind the extracellular domain of the human epidermal growth factor receptor 2 (HER-2) for targeted delivery to cells that overexpress the HER-2 antigen. © 2008 Wiley-VCH Verlag GmbH& Co. KGaA.

引用

页码：1839 / 1843

页数：5

共 28 条

[11] Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine [J].

Kimura, Kenjiro ;

Sawada, Tetsuji ;

Komatsu, Midori ;

Inoue, Masafumi ;

Muguruma, Kazuya ;

Nishihara, Tamahiro ;

Yamashita, Yoshito ;

Yamada, Nobuya ;

Ohira, Masaichi ;

Hirakawa, Kosei .

CLINICAL CANCER RESEARCH, 2006, 12 (16) :4925-4932

[12]

Langer R, 2001, SCIENCE, V293, P58, DOI 10.1126/science.1063273

[13] Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer [J].

Lee, Keun Seok ;

Chung, Hyun Cheol ;

Im, Seock Ah ;

Park, Yeon Hee ;

Kim, Chul Soo ;

Kim, Sung-Bae ;

Rha, Sun Young ;

Lee, Min Young ;

Ro, Jungsil .

BREAST CANCER RESEARCH AND TREATMENT, 2008, 108 (02) :241-250

[14]

MAIER LA, 1991, CANCER RES, V51, P5361

[15] Doxil in breast cancer [J].

Muggia, FM .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :811-811

[16] A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer [J].

O'Byrne, KJ ;

Thomas, AL ;

Sharma, RA ;

DeCatris, M ;

Shields, F ;

Beare, S ;

Steward, WP .

BRITISH JOURNAL OF CANCER, 2002, 87 (01) :15-20

[17] Tumor Imaging using a picomolar affinity HER2 binding affibody molecule [J].

Orlova, A ;

Magnusson, M ;

Eriksson, TLJ ;

Nilsson, M ;

Larsson, B ;

Höidén-Guthenherg, I ;

Widström, C ;

Carlsson, J ;

Tolmachev, V ;

Ståhl, S ;

Nilsson, FY .

CANCER RESEARCH, 2006, 66 (08) :4339-4348

[18] Synthetic affibody molecules:: A novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors [J].

Orlova, Anna ;

Tolmachev, Vladimir ;

Pehrson, Rikard ;

Lindborg, Malin ;

Tran, Thuy ;

Sandstrom, Mattias ;

Nilsson, Fredrik Y. ;

Wennborg, Anders ;

Abrahmsen, Lars ;

Feldwisch, Joachim .

CANCER RESEARCH, 2007, 67 (05) :2178-2186

[19] Biodegradable, polymeric nanoparticle delivery systems for cancer therapy [J].

Pridgen, Eric M. ;

Langer, Robert ;

Farokhzad, Omid C. .

NANOMEDICINE, 2007, 2 (05) :669-680

[20]

PRIMM MV, 1988, CRIT REV THER DRUG, V5, P189

← 1 2 3 →